Maxim Group analyst Jason McCarthy reiterated a Buy rating and lifted his price target on bluebird bio (NASDAQ: BLUE) to ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

bluebird bio (BLUE) PT Raised to $85 at Leerink PartnersDecember 1, 2016 11:26 AM BTIG Affirms bluebird bio (BLUE) at 'Buy' Following bb2121 Phase 1 Data in r/r Multiple MyelomaDecember 1, 2016 7:51 AM bluebird bio (BLUE) PT Raised 10% at Jefferies Following 'Impressive' Initial BCMA CAR-T Ph1 DataDecember 1, 2016 7:47 AM bluebird bio (BLUE) PT Raised to $83 at BMO as bb2121 Shows Promising Efficacy, Clean SafetyDecember 1, 2016 6:18 AM